<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673372</url>
  </required_header>
  <id_info>
    <org_study_id>2015-10-14</org_study_id>
    <secondary_id>2015-10-14</secondary_id>
    <nct_id>NCT02673372</nct_id>
  </id_info>
  <brief_title>Geriatric Ketamine for Pain Management Study</brief_title>
  <official_title>Low-Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department Geriatric Population: A Prospective, Randomized, Double-Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is geared towards geriatric analgesia in the Emergency Department (ED)
      with a goal of reducing the administration of opioid pain medications to elderly patients,
      thereby avoiding the commonly occurring, severe side effects associated with such
      medications, including hypotension, respiratory depression, altered mental status, delirium,
      as well as nausea/vomiting and constipation.

      The primary outcome of the study will be difference in pain score from baseline to 30 minutes
      post-medication administration.

      This project has the potential to change and modify the ED approach to geriatric analgesia by
      virtue of minimizing the use of opioid administration in elderly patients. T
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly patients are making up a greater proportion of the New York State population every
      year as the nation's overall population continues to age at a rapid pace. Acute and chronic
      pain conditions are very common in the geriatric population and it is well recognized that
      pain is undertreated in the elderly. Complicating this important public health problem is
      that changes in physiology that occur in the elderly, such as cognitive decline and impaired
      ability of the liver and kidney to metabolize medications, render opioid administration
      particularly dangerous in the geriatric population. Adverse side effects and increased health
      care utilization are well known hazards associated with opioid use in the elderly.

      Therefore, development of pain management strategies that include non-opioid pain treatment
      modalities has the potential to have a major impact on the health and well-being of New
      Yorkers. This study undertakes a novel strategy intended to reduce opioid consumption in the
      elderly.

      This research project will evaluate the analgesic feasibility and safety of short infusion of
      subdissociative dose of intravenous ketamine compared with short infusion of intravenous
      morphine for controlling pain in ED patients 65 years of age and older, laying the groundwork
      for ketamine to become a safe and viable alternative to opioids in managing geriatric pain in
      the ED. The significance of this project being done at Maimonides Medical center is to lay
      the foundation to providing safer analgesia in geriatric ED patients and moving towards an
      eventual goal of an &quot;opioid-free&quot; ED.

      Methods:

      Study Design:

      This is a prospective, randomized, double-blind trial evaluating and comparing analgesic
      effect of Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion
      (10 min), and intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a
      maximum dose of 10 mg. in elderly adults (age 65 and older) with pain in the ED.

      Study

      Protocol:

      Patient screening, enrollment, and data collection will be performed by study investigators
      and the research fellow. ED pharmacy investigators will maintain the randomization list which
      will be generated prior to commencement of the study, will prepare the medication, and will
      deliver it to the nurse caring for the study participant in a blinded fashion.

      The study will include patients aged 65 and older presenting to the ED with abdominal, flank,
      back, traumatic chest or musculoskeletal pain of (moderate to very severe pain) five or more
      on a standard eleven point (0 - 10; with 0 being no pain to 10 very severe pain) numeric
      rating scale (NRS), and who require opioid analgesia as determined by the treating ED
      attending physician.

      Exclusion criteria will include altered mental status, allergy to morphine or ketamine,
      weight &lt;40kg or &gt;115kg, unstable vital signs (systolic blood pressure &lt;90 or &gt;200 mmHg, heart
      rate &lt;50 or &gt;150 beats per minute, non-traumatic chest pain, headache, and respirations &lt;8 or
      &gt;30 per minute), past medical history of severe renal or hepatic insufficiency, alcohol or
      drug abuse or psychiatric illness; BMI &gt;40; severe COPD

      After patients are evaluated by the treating ED physician and determined to meet eligibility
      criteria, each patient will be approached by a member of the research team for acquisition of
      written informed consent and HIPAA authorization. The on-duty ED pharmacist will prepare
      medications according to the two arms of the study: patients receiving 0.1 mg /kg of morphine
      ; patients receiving 0.3 mg/kg of ketamine.

      The medication will be administered using infusion pump with a 10 minute run time.

      Patients a priori will will be randomized to either of the two arms. A list will be generated
      via SPSS 19.0 from 1 to 90; and SPSS 19.0 will be programmed to randomly assign patients to
      either of the two arms at 10 patient blocks. Thus, for example in patients 1 to 10; SPSS will
      randomly assign 5 patients to the Ketamine group and 5 patients to the morphine group and so
      on for all 90 patients. Therefore, after completion 45 patients will be assigned to the
      Ketamine group and 45 to the morphine group. Antonios will then e-mail the list to Nicholas
      Filk and pharmacy department who will have the list and when a patient is enrolled in the
      study will know which medication to give the patient. Every other investigator and clinician
      would be blinded to the randomization assignment.

      Study investigators will record pain scores, vital signs, and adverse effects at 0, 30, 60,
      90, and 120 minutes.

      Patients who report a pain NRS of five or greater and request additional pain relief will be
      given fentanyl 0.5 mcg/kg as a rescue analgesic. All data, including gender, demographics,
      medical history, and vital signs, will be recorded on data collection sheets and will be
      entered into and analyzed via SPSS 19.0.

      Development of the randomization list, confirmation of written consent acquisition on all
      participants, and statistical analyses will be conducted by the research manager and
      statistician, who will be independent of any data collection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Pain Score at 30 Minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>The primary outcome will be the comparative reduction of NRS pain scores between the 2 groups at 30 minutes. The NRS Pain scale ranges from 0 to 10 (0 being no pain at all to 10 being very severe pain; 5 is moderate pain)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Morphine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.</description>
    <arm_group_label>Morphine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.</description>
    <arm_group_label>Ketamine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ED patients; 65 years of age and older; abdominal, flank, back, traumatic chest, neck
             or musculoskeletal pain; capacity to give verbal or written consent.

        Exclusion Criteria:

          -  ED patients &lt;65 years old; altered mental status; presenting with headache,
             non-traumatic chest pain; allergy to morphine or ketamine; weight &lt;40kg or &gt;115kg,
             unstable vital signs (systolic blood pressure &lt;90 or &gt;180 mmHg; heart rate &lt;5 or &gt;150
             beats per minute; and respirations &lt;8 or &gt;30 per minute), and past medical history of
             severe renal or hepatic insufficiency, alcohol or drug abuse or psychiatric illness;
             Patients with BMI&gt;40; severe COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gibson SJ. Pain and ageing: a comparison of the pain experience over the adult life span. Prog Pain Res Manage. 2003;24:767-90.</citation>
  </reference>
  <reference>
    <citation>Gibson SJ, Farrell M. What is different about pain in older people? Reviews in Analgesia. 2004;8:23-37.</citation>
  </reference>
  <reference>
    <citation>Gibson SJ. Older Persons' Pain: what can we learn? Pain Clin Updat. 2006;14:1-4.</citation>
  </reference>
  <reference>
    <citation>American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Pain Med. 2009 Sep;10(6):1062-83. doi: 10.1111/j.1526-4637.2009.00699.x. Epub 2009 Sep 9. Review.</citation>
    <PMID>19744205</PMID>
  </reference>
  <reference>
    <citation>Leveille SG, Jones RN, Kiely DK, Hausdorff JM, Shmerling RH, Guralnik JM, Kiel DP, Lipsitz LA, Bean JF. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA. 2009 Nov 25;302(20):2214-21. doi: 10.1001/jama.2009.1738.</citation>
    <PMID>19934422</PMID>
  </reference>
  <reference>
    <citation>Linnebur SA, O'Connell MB, Wessell AM, McCord AD, Kennedy DH, DeMaagd G, Dent LA, Splinter MY, Biery JC Jr, Chang F, Jackson RC, Miller SL, Sterling T; ACCP Task Force. Pharmacy practice, research, education, and advocacy for older adults. Pharmacotherapy. 2005 Oct;25(10):1396-430. Review.</citation>
    <PMID>16185185</PMID>
  </reference>
  <reference>
    <citation>Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010 Jan 19;152(2):85-92. doi: 10.7326/0003-4819-152-2-201001190-00006.</citation>
    <PMID>20083827</PMID>
  </reference>
  <reference>
    <citation>Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13;170(22):1968-76. doi: 10.1001/archinternmed.2010.391. Erratum in: Arch Intern Med. 2011 Mar 14;171(5):403.</citation>
    <PMID>21149752</PMID>
  </reference>
  <reference>
    <citation>Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010 Sep;113(3):678-84. doi: 10.1097/ALN.0b013e3181ed09a2.</citation>
    <PMID>20693870</PMID>
  </reference>
  <reference>
    <citation>Strigo IA, Duncan GH, Bushnell MC, Boivin M, Wainer I, Rodriguez Rosas ME, Persson J. The effects of racemic ketamine on painful stimulation of skin and viscera in human subjects. Pain. 2005 Feb;113(3):255-64.</citation>
    <PMID>15661431</PMID>
  </reference>
  <reference>
    <citation>Smith DC, Mader TJ, Smithline HA. Low dose intravenous ketamine as an analgesic: a pilot study using an experimental model of acute pain. Am J Emerg Med. 2001 Oct;19(6):531-2.</citation>
    <PMID>11593484</PMID>
  </reference>
  <reference>
    <citation>Sadove MS, Shulman M, Hatano S, Fevold N. Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg. 1971 May-Jun;50(3):452-7.</citation>
    <PMID>5103784</PMID>
  </reference>
  <reference>
    <citation>Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain. 1999 Aug;82(2):111-25. Review.</citation>
    <PMID>10467917</PMID>
  </reference>
  <reference>
    <citation>Galinski M, Dolveck F, Combes X, Limoges V, Sma√Øl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.</citation>
    <PMID>17499654</PMID>
  </reference>
  <reference>
    <citation>Jennings PA, Cameron P, Bernard S, Walker T, Jolley D, Fitzgerald M, Masci K. Morphine and ketamine is superior to morphine alone for out-of-hospital trauma analgesia: a randomized controlled trial. Ann Emerg Med. 2012 Jun;59(6):497-503. doi: 10.1016/j.annemergmed.2011.11.012. Epub 2012 Jan 13.</citation>
    <PMID>22243959</PMID>
  </reference>
  <reference>
    <citation>Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med. 2010 Sep;28(7):820-7. doi: 10.1016/j.ajem.2009.07.023. Epub 2010 Apr 2.</citation>
    <PMID>20837262</PMID>
  </reference>
  <reference>
    <citation>Ahern TL, Herring AA, Miller S, Frazee BW. Low-Dose Ketamine Infusion for Emergency Department Patients with Severe Pain. Pain Med. 2015 Jul;16(7):1402-9. doi: 10.1111/pme.12705. Epub 2015 Feb 3.</citation>
    <PMID>25643741</PMID>
  </reference>
  <reference>
    <citation>Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014 Nov;21(11):1193-202. doi: 10.1111/acem.12510.</citation>
    <PMID>25377395</PMID>
  </reference>
  <reference>
    <citation>Motov S, Rockoff B, Cohen V, Pushkar I, Likourezos A, McKay C, Soleyman-Zomalan E, Homel P, Terentiev V, Fromm C. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015 Sep;66(3):222-229.e1. doi: 10.1016/j.annemergmed.2015.03.004. Epub 2015 Mar 26.</citation>
    <PMID>25817884</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <results_first_submitted>October 25, 2018</results_first_submitted>
  <results_first_submitted_qc>May 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <keyword>Geriatric, Pain, Ketamine, Emergency Medicine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02673372/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Morphine Group</title>
          <description>intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
Morphine: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.</description>
        </group>
        <group group_id="P2">
          <title>Ketamine Group</title>
          <description>Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
Ketamine: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine Group</title>
          <description>intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
Morphine: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.</description>
        </group>
        <group group_id="B2">
          <title>Ketamine Group</title>
          <description>Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
Ketamine: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.13" spread="8.51"/>
                    <measurement group_id="B2" value="77.27" spread="8.44"/>
                    <measurement group_id="B3" value="77.2" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Pain Score at 30 Minutes</title>
        <description>The primary outcome will be the comparative reduction of NRS pain scores between the 2 groups at 30 minutes. The NRS Pain scale ranges from 0 to 10 (0 being no pain at all to 10 being very severe pain; 5 is moderate pain)</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Morphine Group</title>
            <description>intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
Morphine: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Group</title>
            <description>Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
Ketamine: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Pain Score at 30 Minutes</title>
          <description>The primary outcome will be the comparative reduction of NRS pain scores between the 2 groups at 30 minutes. The NRS Pain scale ranges from 0 to 10 (0 being no pain at all to 10 being very severe pain; 5 is moderate pain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.1"/>
                    <measurement group_id="O2" value="4.2" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Morphine Group</title>
          <description>intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
Morphine: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.</description>
        </group>
        <group group_id="E2">
          <title>Ketamine Group</title>
          <description>Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
Ketamine: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea at 30 minutes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sergey Motov, Director of Research</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-8693</phone>
      <email>smotov@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

